IMPACT OF PRE-TRANSPLANT RITUXIMAB ON SURVIVAL AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR DIFFUSE LARGE B-CELL LYMPHOMA

Incorporation of the anti-CD20 monoclonal antibody rituximab into front-line regimens for diffuse large B-cell lymphoma (DLBCL) has resulted in improved survival. Despite this progress, many patients develop refractory or recurrent DLBCL and then receive autologous hematopoietic stem cell transplant...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Fenske, Timothy S., Hari, Parameswaran N., Carreras, Jeanette, Zhang, Mei-Jie, Kamble, Rammurti T., Bolwell, Brian J., Cairo, Mitchell S., Champlin, Richard E., Chen, Yi-Bin, Freytes, César O., Gale, Robert Peter, Hale, Gregory A., Ilhan, Osman, Khoury, H. Jean, Lister, John, Maharaj, Dipnarine, Marks, David I., Munker, Reinhold, Pecora, Andrew L., Rowlings, Philip A., Shea, Thomas C., Stiff, Patrick, Wiernik, Peter H., Winter, Jane N., Rizzo, J. Douglas, van Besien, Koen, Lazarus, Hillard M., Vose, Julie M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2009
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2913553/
https://ncbi.nlm.nih.gov/pubmed/19822306
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2009.07.017
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados